Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Amyotrophic Lateral Sclerosis: early-phase trial registry
47 of 103 indexed Amyotrophic Lateral Sclerosis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #130 of 28,707 conditions by registered trial count.
103 US clinical trials · 47 currently recruiting · #130 of 28,707 conditions by registered trial count
Amyotrophic Lateral Sclerosis: 103 US clinical trials tracked, 47 recruiting.
Amyotrophic Lateral Sclerosis is the subject of 103 registered US clinical trials on ClinicalTrials.gov, 47 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 40 in Phase 1-2 (earlier-stage). The most active sponsor is University of Miami, running 7 of these trials.
Enrollment posture brief
Registry condition amyotrophic-lateral-sclerosis
OPEN 47 | RECR 46% | LATE 6 | EARLY 40 | RANK #130 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Endothelial Dysfunction (46% recruiting · 46 trials)
Amyotrophic Lateral Sclerosis lists 47 open slots (46% of 103 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Amyotrophic Lateral Sclerosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Amyotrophic Lateral Sclerosis is recruiting above its size-band peers.
47 of 103 indexed trials (45.6%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Amyotrophic Lateral Sclerosis trials is spread across many organizations.
University of Miami accounts for 7 of 103 trials (6.8%). 69 distinct sponsors appear on at least one study for this condition label.
-
Most Amyotrophic Lateral Sclerosis trials plan to enrol fewer than 100 people.
Median target enrolment is 66 among the 103 trials that report a genuine target (sentinel values excluded). 62 of those (60.2%) plan for fewer than 100 participants.
-
Amyotrophic Lateral Sclerosis splits between interventional and observational designs.
68 interventional and 35 observational studies make up this index (66% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
103 total, page 1 of 3
The National Amyotrophic Lateral Sclerosis Registry
Centers for Disease Control and Prevention
NCT01772602
Clinical Research in ALS Study
University of Miami
NCT00136500
NYSCF Scientific Discovery Biobank
New York Stem Cell Foundation Research Institute
NCT06203106
Studies in Amyotrophic Lateral Sclerosis (ALS) and Other Neurodegenerative Motor Neuron Disorders
Mayo Clinic
NCT05474235
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
Mayo Clinic
NCT04363684
ASSESS ALL ALS Study
St. Joseph's Hospital and Medical Center, Phoenix
NCT06578195
ALS Research Collaborative
ALS Therapy Development Institute
NCT06885918
HEALEY ALS Platform Trial - Master Protocol
Merit E. Cudkowicz, MD
NCT04297683
Assessing Perceptual Effects of Interactive Tasks
Penn State University
NCT06828523
Clinical Procedures to Support Research in ALS
University of Miami
NCT03489278
Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures
Target ALS Foundation
NCT05137665
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
xCures
NCT06539169
Novel MRI Biomarkers for Monitoring Disease Progression in ALS
University of Alberta
NCT03362658
Intermuscular Coherence as a Biomarker for ALS
University of Chicago
NCT05104710
PREVENT ALL ALS Study
St. Joseph's Hospital and Medical Center, Phoenix
NCT06581861
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
Prilenia
NCT07322003
The Pre-symptomatic Familial Amyotrophic Lateral Sclerosis (Pre-fALS) Study
University of Miami
NCT00317616
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
AB Science
NCT03127267
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
National Institute of Neurological Disorders and Stroke (NINDS)
NCT03225144
Evaluating Verbal Communication in Structured Interactions: Theoretical and Clinical Implications
Penn State University
NCT06266403
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
Corcept Therapeutics
NCT05407324
AIM's Writing for Healing: A Workshop for Individuals Living With Paralysis
University of Alabama at Birmingham
NCT04721717
Biomarkers in Different Types of Amyotrophic Lateral Sclerosis (ALS) Patients Being Treated With Edaravone
Loma Linda University
NCT04097158
Biospecimen Biorepository for the Study of ALS, ALS-FTD and Similar Neurodegenerative Disorders
Mayo Clinic
NCT05116943
Multicenter ALS Imaging Study
University of Minnesota
NCT06735014
EIM Via the Myolex mScan as an ALS Biomarker
Beth Israel Deaconess Medical Center
NCT06491732
A Study of Ranolazine in ALS
Swathy Chandrashekhar, MBBS
NCT06527222
A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers and Participants With ALS
ProJenX
NCT05279755
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
University of Missouri-Columbia
NCT07478172
Digital Assessment of Speech and Fine Motor Control in ALS
Milton S. Hershey Medical Center
NCT06315673
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Amisodin in Healthy Adult Subjects With Amyotrophic Lateral Sclerosis
PRG Science & Technology Co.
NCT07221240
RAPA-501 Therapy for ALS
Rapa Therapeutics
NCT04220190
Analysis of Human ALS Tissues and Registry of ALS Patients
University of Illinois at Chicago
NCT05067179
Spinal Cord Associative Plasticity for ALS
VA Office of Research and Development
NCT06172621
Imaging Biomarkers in ALS
University of Minnesota
NCT02567136
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
Leigh R. Hochberg, MD, PhD.
NCT00912041
Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis
Johns Hopkins University
NCT06656702
A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)
Insmed Gene Therapy
NCT07290062
Oral Intake of Enteral Nutrition Formula Preceding Placement and Feeding Via GTube and Its Impact on Formula Intolerance in pALS
Andrea Charvet
NCT06609213
Mechanical Insufflation in the Philadelphia Amyotrophic Lateral Sclerosis Cohort (MI-PALS) Study
University of Pennsylvania
NCT06119087
Precise Robotically IMplanted Brain-Computer InterfacE
Neuralink
NCT06429735
Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS
Vector Y Therapeutics
NCT07287397
VOICE: An Early Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for Communication Restoration
Neuralink
NCT07224256
Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia
Leigh R. Hochberg, MD, PhD.
NCT05724173
Investigation on the Cortical Communication (CortiCom) System
Johns Hopkins University
NCT03567213
Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Speech-02)
Leigh R. Hochberg, MD, PhD.
NCT06094205
Connect-One: Early Feasibility Study of Connexus® Brain-Computer Interface (BCI)
Paradromics
NCT07357428
Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment
Amylyx Pharmaceuticals
NCT05021536
TRIAL READY (Clinical Trial Readiness)
University of Miami
NCT03912987
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS
MediciNova
NCT04057898
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 19 |
| Phase 2 | 21 |
| Phase 3 | 6 |
Top Sponsors
Named interventions
Most-linked intervention names on Amyotrophic Lateral Sclerosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Amyotrophic Lateral Sclerosis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Amyotrophic Lateral Sclerosis page
103 registered trials, 47 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 47 Amyotrophic Lateral Sclerosis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Miami sponsors the most Amyotrophic Lateral Sclerosis trials on record, review their full trial history before evaluating a specific study. See University of Miami's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Amyotrophic Lateral Sclerosis condition card totals 103 registered trials; most-linked intervention Placebo; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.